🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We are thrilled to announce our investment into @BioVersys! The antibiotics they are developing target some of the highest-priority drug-resistant pathogens and could deliver significant benefits to patients suffering from life-threatening infections. amractionfund.com/blog-2022/amr-… #AMR

👏 Include vaccines in the fight against drug-resistant #superbugs. 👏 Let's say it louder for the folks in the back. Learn why in our OWOH #podcast with Dr. David Heymann of LSHTM AMR Centre London School of Hygiene & Tropical Medicine Listen here: onehealthtrust.org/news-media/pod… #fightamr #amr

We are pleased to see new international investments by the industry backed AMR Action Fund toward accelerating antibiotic R&D to #beatAMR. Now, global policymakers must also step up & take action toward the development of new #antibiotics. More in Axios ⬇️

January is #OneHealthAwarenessMonth. Why does #OneHealth matter? Find out in our #infographic. Learn about OHT's future headquarters for One Health research, education, and action in our podcast with OHT's Ramanan Laxminarayan. Listen here: onehealthtrust.org/news-media/pod…

Pleased to take part in this important meeting and share the progress made by the private sector as well as the asks we have to governments globally

“No other class of drugs has served humanity’s collective interests like antibiotics have. Yet, they remain dangerously undervalued in today’s marketplace,” writes Martin Heidecker #AMR healtheuropa.com/catalysing-a-n… via Health Europa

Science & innovation delivered medical countermeasures to fight against #COVID19 in record time, but discussions on weakening IP protections risk hindering the #innovation system that enabled this in the first place. Thomas B. Cueni in swissinfo.ch⬇️ bit.ly/3YwSheg

Policymakers must act now on #AMR “because, without timely interventions, investors will continue putting their money into other therapeutic areas; antibiotic companies will go bankrupt; and patients will continue suffering,” writes John Alter globalcause.co.uk/infectious-dis…

“If we don’t get some policy changes and develop the right financial incentives to reward risk taking,” CEO Henry Skinner said, “then the little innovation we have will, I think, dry up nearly completely.” #AMR ft.com/content/2730bf…

📢 Mark your calendars! On the sidelines of the #WHA76 (21-30 May, Geneva), IFPMA is organizing a series of events on #UHC, clinical trials, and #digitalhealth. Information are updated regularly on our website, check it out!👇 ifpma.org/events/

What could the next two decades of change look like in the infectious disease R&D ecosystem? New discussion paper from the Wellcome policy team sets out a vision for ambitious transformation - to help ensure we have the tools 💉💊🔬 we need to face 📈 infections 👇 (1/3)

Thanks to CSEINDIA for organising a great discussion and for the invitation to take part! We need to collaborate, co-operate and innovate to solve the antibiotic development and access crisis. #AMR #stopsuperbugs #antibiotics #antibacterials #pushfunding #pullincentives

#Cancer and #AMR are interlinked, as cancer patients' weakened immune systems leave them unprepared to fight off superbugs. Incentives for #antibiotics R&D can help us address these "twin epidemics."⤵️bit.ly/45dB7WB

“As more drug-resistant diseases, such as #gonorrhea, staphylococcus infections and strains of tuberculosis become increasingly persistent, time is not on our side.” –Innovative Medicines Canada Pamela Fralick windsorstar.com/opinion/letter…

Progress in #globalhealth means people can live longer and healthier lives. Our collaborations help drive different activities in low- and middle-income countries that contribute toward #UHC and #HealthforAll🌎. Explore them on globalhealthprogress.org

New International Pandemic Preparedness Secretariat comment published by The Lancet on delivering the #100DaysMission. It’s critical that we learn the right lessons from the #COVID19 response to better prepare for future pandemics. Read IFPMA’s priorities here: ifpma.org/insights/five-…

This week, I am in New York for the United Nations General Assembly Week 🗽 With three High-Level Meetings on global health and half time for realising the Sustainable Development Goals, we now need to galvanise and look ahead to next year’s meeting on AMR 💊

"This is an area of true need. There has not been a new #antibiotic approved for the treatment of S. aureus bacteremia for over 15 years," Duke University School of Medicine’s Thomas Holland, MD, says. cidrap.umn.edu/antimicrobial-…

Fewer than 30 #antibiotics currently in development target #drugresistant bacteria identified by the World Health Organization (WHO) as the highest priority. More in Scientific American: buff.ly/401UctB

Antibiotic development “is a specialist field, and it takes a long time for people to build up that expertise. So again, there is an urgency to try and stop that brain drain before it's lost further.” Insightful CIDRAP Q&A w/James Anderson cidrap.umn.edu/antimicrobial-… #AMR